Lakeshore biopharma reports unaudited financial results for the first half of fiscal year 2025 and updates full-year guidance

Achieved total revenue of rmb 371.9 million, reflecting a growth of 36.2% yoy achieved gross profit of rmb 307.3 million, a growth of 39.1% yoy gross margin increased to 82.6% from 80.9% in the same period of fy2024 total operating expenses decreased to rmb 276.4 million, down 31.6% yoy recorded net income of rmb 20.6 million, and adjusted net income[1] (non-gaap) of rmb 30.4 million, compared to net loss and adjusted net loss[1] (non-gaap) of rmb 174.5 million in the same period of fy2024 beijing , dec. 19, 2024 /prnewswire/ -- lakeshore biopharma co., ltd. (nasdaq: lsb) ("lakeshore" or the "company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months ended september 30, 2024 ("fy2025h1").
LSB Ratings Summary
LSB Quant Ranking